The clinical innovation stems from the Phase 1 inMMyCAR study, which introduces KLN-1010, an experimental therapeutic agent developed by Kelonia Therapeutics. Diverging from traditional CAR-T cell protocols that necessitate the extraction and external engineering of T cells followed by re-infusion into patients, KLN-1010 employs an in vivo approach. This strategy generates chimeric antigen receptor T cells directly inside the patient’s body, thereby streamlining the therapeutic process, mitigating delays commonly associated with cell manufacturing, and obviating the need for lymphodepleting chemotherapy regimens that often precede CAR-T cell administration.

The in vivo gene placement system (iGPS) platform developed by Kelonia serves as the technological foundation underpinning KLN-1010. By leveraging advanced lentiviral vector delivery systems equipped with envelope modifications and tropism molecules, the platform achieves highly efficient and targeted transduction of T cells in situ. This platform-enhanced specificity fosters robust anti-tumor activity while minimizing off-target effects, thereby potentiating both the safety and effectiveness profiles of the therapy.

Winship Cancer Institute’s rapid activation as the second U.S. site in the global inMMyCAR trial and their distinction as the first institution to administer KLN-1010 on American soil highlight the institute’s leadership in accelerating access to cutting-edge clinical trials. This expedited trial deployment was facilitated through a concerted effort among multidisciplinary teams encompassing myeloma specialists, clinical operations, and research coordinators, emphasizing collaboration as key to cutting bureaucratic delays often hindering trial activation.

Multiple myeloma, a malignancy arising from plasma cells residing in bone marrow, remains challenging to treat despite recent therapeutic progress. Patients with relapsed or refractory forms face limited options and underscore an urgent need for novel therapies that can overcome resistance mechanisms. Traditional CAR-T treatments, although groundbreaking, are hampered by complex logistical challenges and toxicities related to preparative chemotherapy, factors that in vivo CAR-T therapies like KLN-1010 aim to resolve.

Preliminary data presented at the recent American Society of Hematology annual meeting provide a cautiously optimistic outlook, demonstrating encouraging early clinical responses and tolerability in the initial cohort of treated patients. While these findings kindle hope for improved outcomes, investigators underscore the investigational nature of the therapy, necessitating further longitudinal studies to ascertain durability of response and long-term safety implications.

Leading hematology experts at Winship have highlighted the transformative potential of this modality. The in vivo generative paradigm offers prospects for markedly reducing the time to treatment initiation and expanding patient accessibility, particularly for those who might otherwise be ineligible for cell collection or cannot tolerate traditional conditioning regimens. Such advancements could ultimately democratize CAR-T therapy, elevating it from a complex, resource-intensive intervention to a more routine and widely deployable treatment.

Kelonia Therapeutics continues to advance its pipeline using the iGPS platform to develop gene therapies across multiple indications, driven by the ambition to make CAR-T cell therapies accessible when and where patients need them. The successful deployment of KLN-1010 in this trial also sets a precedent for employing in vivo gene therapies in hematologic malignancies, propelling the field towards more patient-friendly, efficient, and scalable immunotherapeutic solutions.

The significance of Winship Cancer Institute’s role as Georgia’s sole National Cancer Institute-designated Comprehensive Cancer Center extends beyond delivering therapies. It provides a vital infrastructure to integrate breakthrough scientific discoveries into clinical care rapidly, fosters robust translational research, and cultivates an ecosystem where patients gain access to promising experimental treatments that might redefine standard-of-care paradigms.

In summary, the initiation of in vivo CAR-T therapy administration in the United States represents a pivotal inflection point in multiple myeloma treatment. It encapsulates the convergence of innovative gene delivery technologies, clinical expertise, and coordinated research efforts aimed at overcoming existing therapeutic barriers. Success in ongoing trials could herald a new era in oncology, wherein gene-modified immune cells are generated seamlessly within patients, offering safer, faster, and more accessible cancer immunotherapies.

Subject of Research: Investigational in vivo CAR-T cell therapy for relapsed and refractory multiple myeloma
Article Title: Winship Cancer Institute Administers First In Vivo CAR-T Therapy in U.S. for Multiple Myeloma
News Publication Date: May 13, 2026
Web References: https://www.keloniatx.com/
Keywords: in vivo CAR-T therapy, multiple myeloma, KLN-1010, chimeric antigen receptor T cells, Kelonia Therapeutics, in vivo gene placement system, phase 1 clinical trial, cancer immunotherapy, investigational therapy, lentiviral vector, hematologic malignancies, Winship Cancer Institute

Recent advances in gene delivery technologies have fueled the development of in vivo CAR-T therapy, an innovative approach that aims to circumvent the traditional ex vivo cell manipulation entirely by reprogramming endogenous T cells directly within the patient’s body. This strategy entails the delivery of CAR-encoding genetic material to native T cells in situ, enabling them to recognize and eliminate target cells without the need for cell extraction and ex vivo expansion. By forestalling elaborate manufacturing steps, in vivo CAR-T holds the promise of streamlined treatment timelines, reduced financial burden, and enhanced scalability, potentially democratizing access to this transformative therapeutic modality.

Central to the success of in vivo CAR-T therapies is the advancement of sophisticated delivery platforms engineered to achieve efficient, selective, and safe gene transfer to T cells. Among these, viral vectors such as lentivirus and adeno-associated virus (AAV) remain the mainstays, offering high transduction efficiency and durable CAR expression. Lentiviral vectors integrate into the host genome, conferring stable and persistent CAR expression—an attribute particularly advantageous for oncologic applications where sustained tumor surveillance is critical. AAV vectors, favored for their favorable safety profile and tissue tropism, are also being evaluated as vehicles for CAR gene delivery. However, viral vectors must be carefully optimized to minimize immunogenicity and off-target transduction, which could complicate therapeutic safety and efficacy.

In parallel, non-viral lipid nanoparticle (LNP)-based delivery systems have garnered significant attention for their ability to transport mRNA encoding CAR constructs directly into T cells. These LNPs enable transient and controllable CAR expression, an appealing feature for autoimmune and inflammatory disorders where reversible modulation of immune effector functions is desirable. Unlike integrating viral vectors, mRNA therapy offers a safer profile by eliminating the risk of insertional mutagenesis. Furthermore, LNP technology benefits from scalable manufacturing platforms that have been validated extensively in contemporary mRNA vaccines, underscoring their clinical translational potential.

The clinical landscape of in vivo CAR-T therapy has evolved remarkably over the past two years, shifting from preclinical experimentation to early-phase human trials with promising outcomes. Studies in hematologic malignancies have demonstrated that in vivo-generated CAR-T cells can achieve measurable anti-tumor activity while maintaining a tolerable safety profile, thereby validating the feasibility of this in situ gene-programming approach. Notably, applications have extended beyond oncology into autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, where transient CAR expression mediated by mRNA delivery could safely recalibrate dysregulated immune responses.

Emergence of solid tumors into the investigational pipeline for in vivo CAR-T therapy represents a critical milestone in addressing longstanding challenges associated with CAR-T efficacy in solid malignancies. The heterogeneous tumor microenvironment, antigen heterogeneity, and immune suppressive factors have traditionally limited CAR-T therapy success in these cancers. Nonetheless, evolving delivery platforms focused on precise T-cell targeting and tunable expression levels, bolstered by multidisciplinary engineering innovations, now provide a tangible pathway to surmount these barriers.

Despite the promising trajectory, several translational challenges remain pivotal for clinical maturation and broader adoption of in vivo CAR-T therapy. Achieving selective transfection of T cells without affecting non-target cell populations demands highly specific targeting ligands and delivery modalities. Controlling CAR-T cell persistence through inducible safety switches or dosage regulation mechanisms is also essential to balance therapeutic efficacy with manageable toxicity. Immune responses elicited against viral vectors or nanoparticle components could hinder repeat dosing or provoke adverse reactions, emphasizing the necessity for immunomodulatory strategies in vector design.

Regulatory considerations for in vivo CAR-T encompass the intersection of gene and cell therapy frameworks, requiring harmonized guidelines to address the unique attributes of in situ gene programming. Identifying robust biomarkers and pharmacodynamic endpoints capable of capturing the dynamic behavior of CAR-T cells generated within the body is critical for regulatory approval and clinical monitoring. Long-term follow-up to surveil potential safety risks such as insertional mutagenesis, off-target effects, and immune-mediated toxicities remains a central component of the translational roadmap.

In summary, in vivo CAR-T therapy heralds a transformative evolution in adoptive immunotherapy, redefining the conventional paradigm by effectively turning the patient’s body into a bioreactor for CAR-T cell generation. Harnessing cutting-edge delivery systems, clinical validation, and integrated translational strategies, this approach aims to democratize access to next-generation cellular immunotherapies across oncology and complex autoimmune disorders. As the scientific community continues to unravel mechanistic insights and optimize engineering solutions, the coming years promise profound advancements shaping the future landscape of personalized, gene-programmed immunotherapy.

This burgeoning field is supported by pioneering institutions such as the National Cancer Center and the Chinese Academy of Medical Sciences, which are at the forefront of translating benchside innovations into viable clinical applications. Through rigorous research, clinical trials, and cross-disciplinary collaborations, these entities contribute substantially to realizing the full potential of in vivo CAR-T cell technology to improve patient outcomes globally.

The integration of viral and non-viral vector research, immune biology, and computational modeling will be paramount to address the remaining bottlenecks. As regulatory pathways evolve and the first waves of in vivo CAR-T products move towards commercialization, patients and clinicians alike stand to benefit from therapies that are not only highly effective but also more accessible, safer, and responsive to individualized needs.

The momentum built around in vivo CAR-T therapy solidifies its role as a strategic frontier in the convergence of gene therapy and immuno-oncology. By continuing to innovate at the nexus of molecular engineering, clinical science, and translational medicine, this approach has the potential to radically transform therapeutic landscapes and redefine standards of care in cancer and autoimmunity.

Subject of Research:
In vivo Generation of Chimeric Antigen Receptor T-Cells for Cancer and Autoimmune Disease Therapy

Article Title:
In vivo CAR-T Cell Therapy: Engineering the Future of Adoptive Immunotherapy

News Publication Date:
2026

Web References:
Not provided

References:
Not provided

Image Credits:
©Science China Press

Keywords:
CAR-T therapy, in vivo gene delivery, lipid nanoparticle, viral vectors, lentivirus, adeno-associated virus, mRNA delivery, autoimmune diseases, hematologic malignancies, solid tumors, immunotherapy, gene therapy